**REGISTERED COMPANY NUMBER: 05017662 (England and Wales) REGISTERED CHARITY NUMBER: 1106320**
## **Report of the Trustees and**
**Unaudited Financial Statements for the Year Ended 31 December 2024**
## **for**
## **THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
**(A COMPANY LIMITED BY GUARANTEE)**
Elsby & Co (Sywell) Ltd Chartered Accountants 155 Wellingborough Road Rushden Northamptonshire NN10 9TB
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Contents of the Financial Statements for the year ended 31 DECEMBER 2024**
||**Page**|
|---|---|
|**Report of the Trustees**|1 to 5|
|**Independent Examiner's Report**|6|
|**Statement of Financial Activities**|7|
|**Balance Sheet**|8 to 9|
|**Cash Flow Statement**|10|
|**Notes to the Cash Flow Statement**|11|
|**Notes to the Financial Statements**|12 to 18|
|**Detailed Statement of Financial Activities**|19 to 20|
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Report of the Trustees**
## **for the year ended 31 DECEMBER 2024**
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 (as amended by Update Bulletin 1 published on 2 February 2016).
## **OBJECTIVES AND ACTIVITIES**
## **Objectives and aims**
The objectives of the company, as set out in the Memorandum of Association as amended by Special Resolution, are to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research directed towards the development and evaluation of treatment of such disease and disorders. The Trustees confirm that they have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing the association's aims and objectives and in planning future activities.
The Trustees carry out these objects by:
- Having educational meetings for medical professionals to attend to further their knowledge and advance education, awareness and research into liver disease.
- Supporting special interest groups to further education of specific areas of liver disease.
To assess success in the reporting period, BASL aims to maintain and increase membership, provide educational events; predominantly the Annual Scientific Meeting. Success is also assessed based on sufficient funds being maintained to allow these activities to take place.
## **Contribution**
The contribution of each member is limited to £1 in the event of a dissolution of the Company.
Page 1
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Report of the Trustees**
## **for the year ended 31 DECEMBER 2024**
## **ACHIEVEMENT AND PERFORMANCE Charitable activities**
## **BASL Annual Meeting (incorporating the annual BTLG and BLNA meeting)**
The 2024 BASL Annual meeting was held at the Harrogate Convention Centre and proved to be a great success providing interaction and learning opportunities. There were 639 delegates across all three meetings which made an excellent surplus. The Sheila Sherlock prize went to Dr Wenhao Li and Dr Felicity Williams received the Andrew Burroughs Young Investigator award.
## **BASL Schools**
BASL Schools are small group meetings provided free of charge to trainee members in Gastroenterology and Hepatology that deliver structured education and interaction with experts in the field. These help the charity to meet its objectives by committing to improving clinical education and training for tomorrow's Hepatology Consultants, Trainees interested in transplantation and anaesthesia.
These were held as 6 interactive Webinars and one face to face meeting. These proved to be a great success and feedback was excellent.
## **BASL Xtra**
This is an online educational conference and was the second one to be held. This a multi-professional, topic focused educational online event. Attendance and surplus were excellent.
## **BASL Introduction to Hepatology Day**
The meeting was held in London. This was deemed to be a great success and provided a surplus.
## **BVHG Meetings**
No meetings were held for BVHG in 2024.
## **BASL Basic Science Retreat**
This was held in London and made a small surplus. The Foundation for Liver Research organised the event on behalf of BASL. This was very popular and well attended.
## **Special Interest Groups**
BASL provides ongoing administrative support to a number of established Special Interest Groups (SIGs) whose remit is to promote and encourage collaborative research and clinical trials in liver disease.
## **HCC-UK Annual Meeting**
This was held at the Clare College Cambridge. This was very well attended and made a small deficit.
## **CCA-UK Annual Meeting**
This was held at Hallam Conference Centre and made an excellent surplus. Changes are being made for future years to increase attendance.
## **BAAL**
A meeting was not held in 2024.
## **BHPG Educational Meeting**
One meeting was held in November in 2024 and made an excellent surplus.
## **BASL MDT Educational Webinars**
Two webinars were held in 2024, making a small surplus. Three more are planned for 2025.
## **Secretariat**
Secretariat services were provided by Executive Business Support Ltd.
Page 2
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Report of the Trustees for the year ended 31 DECEMBER 2024**
## **FINANCIAL REVIEW**
## **Financial position**
Detailed finance reports are produced for the Trustees for every governing board meeting. The Trustees aim to achieve a surplus or breakeven for every educational meeting. The results for the year are shown on page 6. The Trustees aim to hold sufficient reserves to support key meetings in the event of potential shortfalls in income. The membership and subscriptions database has been updated and clarified and the charity currently has 1,629 (2023: 1,624) active members. The BASL website continued to provide a good platform for providing news and information as well as serving as an interactive communications and an education hub for members.
The charity managed to achieve income of £647,239 (2023: £533,539) during the year.
Cash reserves have increased to £334,084 (2023: £261,210) due to the charity continuing to hold some events on a virtual basis as well as face to face. This is mainly due to increased sponsorship income from Pharmaceutical companies.Of these cash reserves, £22,377 is held in restricted funds (2023: £22,377).
To ensure a balanced picture of the charity's progress against its objectives, sufficient funds are maintained to allow the desired educational events held to continue to take place. The Trustees believe that the charity has sufficient reserves to continue and hopes to achieve a greater surplus in 2025 with the aim of continuing to hold events on a face to face basis, as well as some on a virtual basis.
The key performance indicators to explain outputs achieved by activities are the level and numbers of members increasing, as well as maintaining delegate members at educational events. On both of these indicators, the charity has performed well in the year.
## **Reserves policy**
Reserves are needed as sponsorship by Pharmaceutical Companies of educational events, which are one of the key objectives of BASL, can drop suddenly depending on the current focus of the Pharmaceutical Companies. As stated in the Articles of Association: The Association will aim to retain sufficient capital funds in reserve to permit it to conduct its activities as defined by the Governing Board for a period of two years in the absence of any income over this period.
At the balance sheet date, the charity had free reserves of £319,313 (2023: £195,256). Of these reserves, £22,377 is held in restricted funds (2023: £23,377) and £296,936 is held in unrestricted funds (2023: £172,878).
The charity always hopes to retain reserves in unrestricted funds to cover 24 months operational costs. At the end of the accounting period, free reserves had increased but continue to remain below the 24 month target. However, the charity anticipates that free reserves will continue to grow over the coming years and will return to former levels. The Trustees are confident that the charity retains sufficient funds to continue operating and furthering its charitable purpose.
## **FUTURE DEVELOPMENTS**
The Trustees aim to continue to provide educational meetings and other member benefits in accordance with the objectives of the Charity. The experience of the pandemic has resulted in the ability to run meetings on a virtual basis to ensure events still take place, making meetings accessible to members and meaning external risk factors are more manageable.
The Governing Board commenced discussions and plans for a new upgraded website providing increased functionality, reporting and member experience for 2025. The final decision was to be made at a Governing Board meeting following the annual meeting, which would give an indication of the financial position for the year.
## **STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document**
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.
Page 3
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Report of the Trustees for the year ended 31 DECEMBER 2024**
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
## **Induction and training of new trustees**
Newly elected Trustees attend quarterly meetings with the Chairperson and the governing board to observe the provision of services to members. They are also given guidance which include an outline of their role and a handover from the outgoing Trustee.
The charity makes decisions through its governing board. Policies and procedures for induction and training of Trustees is supported by the current and outgoing Trustees.
## **REFERENCE AND ADMINISTRATIVE DETAILS**
## **Registered Company number**
05017662 (England and Wales)
## **Registered Charity number**
1106320
## **Registered office**
St Chad's Road Lichfield Staffordshire WS13 6TJ
## **Trustees**
Dr T J S Cross Consultant Hepatologist Dr T J Kendall Senior Clinical Fellow In Pathology Dr I A C Rowe University Clinical Academic Fellow Dr V Snowdon Consultant Hepatologist Ms M B Clayton Lecturer In Liver Care Professor M E Cramp Consultant Hepatologist Dr A M Elsharkawy Consultant Hepatologist Professor R Mookerjee Professor of Translational Hepatology Dr M Allison Consultant Hepatologist Dr S Chokshi Acting Director & Chief Scientific Offic Dr O A A Elshaarawy Professor P Kennedy Consultant Hepatologist and Gastroentero Mr J A Richard Doctor Dr L Vine Consultant Hepatologist (appointed 1.11.24) Dr V Patel Consultant Hepatologist (appointed 1.11.24) Dr D Joshi Transplant Hepatologist&HPB Endoscopist (appointed 1.11.24)
## **Independent Examiner**
Carl Elsby ACA Elsby & Co (Sywell) Ltd Chartered Accountants 155 Wellingborough Road Rushden Northamptonshire NN10 9TB
Page 4
THE 8RmSH ASSOCIATION FOR THE STUDY OF
HE LIV
Re ort of the Trustees
ear ended 31 DECEMBER 2024
This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2Q)6 relating
to small companies.
Approved by order of the board of trustees on .
and signed on its behalf by:
Elsharkawy - Trustee
Page S
## **Independent Examiner's Report to the Trustees of The British Association for the Study of the Liver**
**Independent examiner's report to the trustees of The British Association for the Study of the Liver ('the Company')** I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.
## **Responsibilities and basis of report**
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Carl Elsby ACA
Elsby & Co (Sywell) Ltd Chartered Accountants 155 Wellingborough Road Rushden Northamptonshire NN10 9TB
Date: .............................................15/07/2025
Page 6
## **THE BRITISH ASSOCIATION FOR THE STUDY OF**
## **THE LIVER**
## **Statement of Financial Activities**
## **for the year ended 31 DECEMBER 2024**
|Unrestricted
funds
Notes
£
**INCOME AND ENDOWMENTS FROM**
Membership subscriptions
3
110,935
Conference fees & sponsorship income
4
528,508
Interest receivable
5
3,029
Legacies and donations
4,767
**Total**
647,239
**EXPENDITURE ON**
**Conference costs**
Direct conference costs
6
310,283
Other associated conference costs
7
207,794
518,077
Other
5,105
**Total**
523,182
**NET INCOME**
124,057
**RECONCILIATION OF FUNDS**
Total funds brought forward
172,879
**TOTAL FUNDS CARRIED FORWARD**
296,936|Restricted
funds
£
-
-
-
-
-
-
-
-
-
-
-
22,377
22,377|2024
Total
funds
£
110,935
528,508
3,029
4,767
647,239
310,283
207,794
518,077
5,105
523,182
124,057
195,256
319,313|2023
Total
funds
£
116,383
413,049
4,107
-
533,539
287,534
189,113
476,647
9,014
485,661
47,878
147,378
195,256|
|---|---|---|---|
## **CONTINUING OPERATIONS**
All income and expenditure has arisen from continuing activities.
The notes form part of these financial statements
Page 7
## **THE BRITISH ASSOCIATION FOR THE STUDY OF**
## **THE LIVER**
## **Balance Sheet**
## **31 DECEMBER 2024**
|Unrestricted
funds
Notes
£
**FIXED ASSETS**
Investments
12
1
**CURRENT ASSETS**
Debtors: amounts falling due within one year
13
53,331
Cash at bank
311,707
365,038
**CREDITORS**
Amounts falling due within one year
14
(39,796)
**NET CURRENT ASSETS**
325,242
**TOTAL ASSETS LESS CURRENT LIABILITIES**
325,243
**CREDITORS**
Amounts falling due after more than one year
15
(28,307)
**NET ASSETS**
296,936
**FUNDS**
16
Unrestricted funds:
General fund
Restricted funds:
BASL nurses fund
CCA UK Neil Blenkinsop donation for research
only
**TOTAL FUNDS**|Restricted
funds
£
-
-
22,377
22,377
-
22,377
22,377
-
22,377|2024
Total
funds
£
1
53,331
334,084
387,415
(39,796)
347,619
347,620
(28,307)
319,313
296,936
6,627
15,750
22,377
319,313|2023
Total
funds
£
1
40,753
261,210
301,963
(69,926)
232,037
232,038
(36,782)
195,256
172,879
6,627
15,750
22,377
195,256|
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.
The notes form part of these financial statements
continued...
Page 8
THE BRMSH ASSOCIATION FOR THE STUDY OF
HE UVE
Balance Sheet- continued
31 DECEMBE
The trustees acknowledge their responsibilities for
la)
ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the
Companies Act 2006 and
preparing financial statements which give a true and fair view of the state of affairs of the charitable company
as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the
requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies
Act 2006 relating to financial statements, so far as applicable to the charitable company.
{bl
These financial statements have been prepared in accordance with the provisions applicable to charitable companies
subject to the small companie5 regime.
The financial statements were approved by the Board of Trustees and authorised for issue
..3fv.rnL..1. L•L.f.. and were signed on its behalf bv:
on
Dr
harkawy - Trustee
The notes form part of these financial statements
Page 9
## **THE BRITISH ASSOCIATION FOR THE STUDY OF**
## **THE LIVER**
## **Cash Flow Statement**
|**for the year ended 31 DECEMBER**
Notes
**Cash flows from operating activities**
Cash generated from operations
1
Net cash provided by operating activities
**Cash flows from investing activities**
Interest received
Net cash provided by investing activities
**Change in cash and cash equivalents in the**
**reporting period**
**Cash and cash equivalents at the beginning**
**of the reporting period**
**Cash and cash equivalents at the end of**
**the reporting period**|**for the year ended 31 DECEMBER**|**2024**
2024
£
69,845
69,845
3,029
3,029
72,874
261,210
334,084|2023
£
50,366
50,366
4,107
4,107
54,473
206,737
261,210|
|---|---|---|---|
The notes form part of these financial statements
Page 10
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Cash Flow Statement**
## **for the year ended 31 DECEMBER 2024**
## **1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**
|**Net income for the reporting period (as per the Statement of Financial**
**Activities)**
**Adjustments for:**
Interest received
Increase in debtors
(Decrease)/increase in creditors
**Net cash provided by operations**|2024
£
124,057
(3,029)
(12,578)
(38,605)
69,845|2023
£
47,878
(4,107)
(22,860)
29,455
50,366|
|---|---|---|
## **2. ANALYSIS OF CHANGES IN NET FUNDS**
|**Net cash**|At 1.1.24
Cash flow
At 31.12.24
£
£
£|
|---|---|
|Cash at bank|261,210
72,874
334,084|
||261,210
72,874
334,084|
|**Total**|261,210
72,874
334,084|
The notes form part of these financial statements
Page 11
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Financial Statements**
## **for the year ended 31 DECEMBER 2024**
## **1. ACCOUNTING POLICIES**
## **General information**
The charity is a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is Executive Business Support, Davidson Road, Lichfield, Staffordshire, England, WS14 9DZ.
## **Basis of preparing the financial statements**
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.
The presentational currency of BASL is considered to be pounds sterling and the financial statements are rounded to the nearest pound.
## **Incoming resources**
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
Income received for a specific restricted purpose is credited to a separate restricted fund which is shown in a note to the financial statements. Total incoming resources credited to restricted funds are disclosed on the statement of financial activities which also shows incoming resources in respect of unrestricted funds.
Conference income represents fees and sponsorship received in respect of conference's organised in pursuit of the company's charitable objectives.
Income associated with conferences of future accounting periods is treated as deferred income.
## **Resources expended**
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Resources expended are included in the statement of financial activities on an accrual basis exclusive of VAT. All irrecoverable VAT is charged against the category of resources expended for which it was incurred.
## **Taxation**
The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects.
## **Fund accounting**
Unrestricted funds are donations and other incoming resources received or generated for the general charitable purposes of the charity.
Within unrestricted funds are designated funds. The nature of each of the designated funds is referred to within the report of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
continued...
Page 12
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Financial Statements - continued**
## **for the year ended 31 DECEMBER 2024**
## **1. ACCOUNTING POLICIES - continued**
## **Debtors and creditors**
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
## **Cash and cash equivalents**
Cash and cash equivalents include cash in hand and deposits held at call with banks.
## **2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**
In preparing the financial statements it is necessary to make certain judgements, estimates and assumptions that affect the amounts recognised int he financial statements.
In the view of the trustees in applying the accounting policies adopted, no judgements were required that have a significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions made carry a significant risk of material adjustment in the next financial year.
## **3. MEMBERSHIP SUBSCRIPTIONS**
**----- Start of picture text -----**
||||
|---|---|---|
|2024|2023|
|£|£|
|Grants|-|12,729|
|Subscriptions|110,935|103,654|
|110,935|116,383|
**----- End of picture text -----**
Grants receivable are credited to the Statement of Financial Activities (SOFA) in the year for the year for which they are received. Deferred income represents amounts received for future periods and is released to incoming resources in the period for which it has been received.
## **4. CONFERENCE FEES & SPONSORSHIP INCOME**
**----- Start of picture text -----**
||||
|---|---|---|
|2024|2023|
|£|£|
|Conference income|528,508|413,049|
**----- End of picture text -----**
continued...
Page 13
**THE BRITISH ASSOCIATION FOR THE STUDY OF**
**THE LIVER**
## **Notes to the Financial Statements - continued**
## **for the year ended 31 DECEMBER 2024**
## **5. INTEREST RECEIVABLE**
|Interest receivable
**6.**
**DIRECT CONFERENCE COSTS**
Annual conference costs
Support to Non-BASL activities
**7.**
**OTHER ASSOCIATED CONFERENCE COSTS**
Travel & hotels
Artwork/design & print
CPD application
Bank charges
Website
Secretarial support costs
EBS Costs
Partial exemption input VAT
**8.**
**SUPPORT COSTS**
Other resources expended
**9.**
**NET INCOME/(EXPENDITURE)**
Net income/(expenditure) is stated after charging/(crediting):
Accountancy fees|2024
2023
£
£
3,029
4,107
2024
2023
£
£
291,183
274,284
19,100
13,250
310,283
287,534
2024
2023
£
£
2,950
12,511
230
4,216
-
956
5,251
5,282
6,489
4,408
7,918
8,044
186,865
170,635
(1,909)
(16,939)
207,794
189,113
Governance
costs
£
5,105
2024
2023
£
£
5,105
5,012|
|---|---|
continued...
Page 14
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Financial Statements - continued for the year ended 31 DECEMBER 2024**
## **10. TRUSTEES' REMUNERATION AND BENEFITS**
No trustees received any remuneration during the current or prior year.
## **Trustees' expenses**
Travel and speaker expenses totalling £635.29 (2023; £525.36) were reimbursed to 2 (2023; 4) trustees during the year.
## **11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**
|Unrestricted
funds
£
**INCOME AND ENDOWMENTS FROM**
Membership subscriptions
116,383
Conference fees & sponsorship income
413,049
Interest receivable
4,107
**Total**
533,539
**EXPENDITURE ON**
**Conference costs**
Direct conference costs
287,534
Other associated conference costs
189,113
476,647
Other
9,014
**Total**
485,661
**NET INCOME**
47,878
**RECONCILIATION OF FUNDS**
Total funds brought forward
125,001
**TOTAL FUNDS CARRIED FORWARD**
172,879|Restricted
funds
£
-
-
-
-
-
-
-
-
-
-
22,377
22,377|Total
funds
£
116,383
413,049
4,107
533,539
287,534
189,113
476,647
9,014
485,661
47,878
147,378
195,256|
|---|---|---|
continued...
Page 15
**THE BRITISH ASSOCIATION FOR THE STUDY OF**
**THE LIVER**
## **Notes to the Financial Statements - continued**
## **for the year ended 31 DECEMBER 2024**
## **12. FIXED ASSET INVESTMENTS**
**----- Start of picture text -----**
|||
|---|---|
|Unlisted|
|investments|
|£|
|MARKET VALUE|
|At 1 January 2024 and 31 December 2024|1|
|NET BOOK VALUE|
|At 31 December 2024|1|
|At 31 December 2023|1|
**----- End of picture text -----**
There were no investment assets outside the UK.
**----- Start of picture text -----**
||||
|---|---|---|
|13.|DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR|
|2024|2023|
|£|£|
|Trade debtors|16,285|32,418|
|VAT|3,606|-|
|Prepayments|33,440|8,335|
|53,331|40,753|
|14.|CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR|
|Deferred income|
|2024|2023|
|£|£|
|Deferred income at 1 January 2024|23,780|23,000|
|Resources deferred during the year|5,820|23.780|
|Amounts released from prior year|(23,780)|(23,000)|
|Deferred income at 31 December 2024|5,820|23,000|
**----- End of picture text -----**
Deferred income relates to income received in the year specifically relating to performance conditions to be met in the following year.
continued...
Page 16
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Financial Statements - continued**
## **for the year ended 31 DECEMBER 2024**
## **15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**
|Bursary Fund - support for members to attend meetings
BLNA restricted fund|2024
£
15,828
12,479
28,307|2023
£
24,303
12,479
36,782|
|---|---|---|
## **16. MOVEMENT IN FUNDS**
|**Unrestricted funds**
General fund
**Restricted funds**
BASL nurses fund
CCA UK Neil Blenkinsop donation for
research only
**TOTAL FUNDS**
Net movement in funds, included in the above are as follows:
**Unrestricted funds**
General fund
**TOTAL FUNDS**|At 1.1.24
£
172,879
6,627
15,750
22,377
195,256
Incoming
resources
£
647,239
647,239|Net
movement
At
in funds
31.12.24
£
£
124,057
296,936
-
6,627
-
15,750
-
22,377
124,057
319,313
Resources
Movement
expended
in funds
£
£
(523,182)
124,057
(523,182)
124,057|
|---|---|---|
continued...
Page 17
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Notes to the Financial Statements - continued**
## **for the year ended 31 DECEMBER 2024**
## **16. MOVEMENT IN FUNDS - continued**
## **Comparatives for movement in funds**
|At 1.1.23
£
**Unrestricted funds**
General fund
125,001
**Restricted funds**
BASL nurses fund
6,627
CCA UK Neil Blenkinsop donation for
research only
15,750
22,377
**TOTAL FUNDS**
147,378
Comparative net movement in funds, included in the above are as follows:
Incoming
resources
£
**Unrestricted funds**
General fund
533,539
**TOTAL FUNDS**
533,539|Net
movement
At
in funds
31.12.23
£
£
47,878
172,879
-
6,627
-
15,750
-
22,377
47,878
195,256
Resources
Movement
expended
in funds
£
£
(485,661)
47,878
(485,661)
47,878|
|---|---|
## **17. RELATED PARTY DISCLOSURES**
There were no related party transactions for the year ended 31 December 2024.
Page 18
**THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER**
## **Detailed Statement of Financial Activities**
|**for the year ended 31 DECEMBER 2024**
**INCOME AND ENDOWMENTS**
**Membership subscriptions**
Grants
Subscriptions
**Conference fees & sponsorship income**
Conference income
**Interest receivable**
Interest receivable
**Legacies and donations**
Legacy donations
Donations
**Total incoming resources**
**EXPENDITURE**
**Direct conference costs**
Annual conference costs
Support to Non-BASL activities
**Other associated conference costs**
Travel & hotels
Artwork/design & print
CPD application
Bank charges
Website
Secretarial support costs
EBS Costs
Partial exemption input VAT
**Support costs**
**Governance costs**
Accountancy fees
Carried forward|2024
£
-
110,935
110,935
528,508
3,029
500
4,267
4,767
647,239
291,183
19,100
310,283
2,950
230
-
5,251
6,489
7,918
186,865
(1,909)
207,794
5,105
5,105|2023
£
12,729
103,654
116,383
413,049
4,107
-
-
-
533,539
274,284
13,250
287,534
12,511
4,216
956
5,282
4,408
8,044
170,635
(16,939)
189,113
5,012
5,012|
|---|---|---|
This page does not form part of the statutory financial statements
Page 19
**THE BRITISH ASSOCIATION FOR THE STUDY OF**
**THE LIVER**
## **Detailed Statement of Financial Activities**
## **for the year ended 31 DECEMBER 2024**
|**Governance costs**
Brought forward
Other legal and professional
Total resources expended
**Net income**|2024
£
5,105
-
5,105
523,182
124,057|2023
£
5,012
4,002
9,014
485,661
47,878|
|---|---|---|
This page does not form part of the statutory financial statements
Page 20